antigen-1

MART-1 nonamer antigen (LAGIGILTV) is a melanoma antigen recognizable by T cells. It functions as a superagonist by enhancing the immunological response of specific T cells when induced ex vivo. Additionally, MART-1 nonamer antigen serves as a peptide model for designing antitumor vaccines.

Mage-1 Antigen (161-169), human is a polypeptide molecule with the sequence EADPTGHSY.

Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6 22 90 15 20 20 57 58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.

Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6 20 22 nM for Raf-1 VEGFR-3 B-Raf).

Lifitegrast (SAR 1118) is an antagonist of lymphocyte function-associated antigen-1.

Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα β, PDGFR, and Axl.

NCGC00262650 is an inhibitor of AMA1-RON2 interaction and c-Src tyrosine kinase activity.

PROTAC IDO1 Degrader-1, a pioneering compound, efficiently targets indoleamine 2,3-dioxygenase 1 (IDO1) for ubiquitination and degradation by recruiting IDO1 to the CRBN E3 ligase, thereby facilitating its entry into the ubiquitin-proteasome system (UPS) with a DC50 of 2.84 μM. This compound also moderately enhances the tumor-killing efficacy of HER2 CAR-T cells[1].

CEF19, Epstein-Barr Virus latent NA-3A (458-466), is a peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain).

A 286982 is an inhibitor that blocks the integrin-ligand interaction between leukocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1.

PSA1 141-150 acetate is used in the immunotherapy of cancer experiments that is a prostate specific antigen 1 peptide.

Asoxime dichloride (Tert-Butyl2-(2-hydroxyethyl)-1-pyrrolidinecarboxylate) is an antagonist to acetylcholine receptors (AChRs) including the nicotinic receptor, α7 nAChR. Asoxime dichloride (HI-6) can be used as an antigen and improves vaccination efficacy in the nervous system. Asoxime dichloride involves in modulating immunity response.

BI-1950 is a highly potent inhibitor of lymphocyte function-associated antigen-1 (LFA-1), an essential component in normal immune system function and a significant target for drug discovery [1].

AH1, an immunodominant antigen derived from the gp70 product of endogenous MuLV, serves as the CTL-immunodominant epitope in CT26 colon carcinoma [1] [2].

HBV Seq1 aa:93-100 is a peptide fragment of the hepatitis B virus (HBV) core antigen spanning amino acids 93 to 100 [1].

FMOC-L-THR (AZP-531) is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight. The O-glycosidic linkage and the O-acetyl protection in this building block is stable to both piperidine and TFA, making it completely compatible with standard protocols in Fmoc solid phase peptide synthesis. The Tn antigen is a tumor-associated carbohydrate antigen that is not normally expressed in peripheral tissues or blood cells. Expression of this antigen, which is found in a majority of human carcinomas of all types, arises from a blockage in the normal O-glycosylation pathway in which glycans are extended from the common precursor GalNAcα1-O-Ser Thr (Tn +antigen)[1].

DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstrating antiproliferative activity. It activates caspase-3 and cleaved poly ADP-ribose polymerase, inducing apoptosis. Furthermore, DPP enhances the maturation and antigen presentation of dendritic cells and exhibits in vivo safety [1].

DYSP-C34, a potent ultrasound (US)-triggered multifunctional molecular machine, exhibits a favorable lipophilic hydrophilic balance, enhanced US-induced reactive oxygen species (ROS) production, and improved cellular permeability. These properties contribute to its superior tumor-targeting efficiency and significant tumor regression when used in sonodynamic therapy (SDT). Additionally, DYSP-C34 demonstrates mild immunogenicity by directly stimulating antigen-presenting cells (APCs) [1].

Maceneolignan A, a natural product isolated from the aril of Myristica fragrans (Myristicaceae), inhibits β-hexosaminidase release in RBL-2H3 cells, exhibiting an IC50 of 48.4 μM. Additionally, it suppresses TNF-α release in antigen-stimulated RBL-2H3 cells with an IC50 of 63.7 μM [1].

Dihydrodehydrodiconiferyl alcohol 9-O-α-L-rhamnopyranoside (Compound 1), a lignan with anti-HBV activity, selectively targets the HBV surface antigen (HBsAg) with an IC50 of 0.58 mM, while its activity against the HBV e antigen (HBeAg) is significantly lower, with an IC50 of >2.4 mM. This compound can be isolated from the plant star anise [1].

Cholicamideβ (compound 6), a self-assembling small molecule cancer vaccine adjuvant, forms low cytotoxicity virus-like particles and upon binding to peptide antigens, enhances dendritic cell-mediated antigen presentation and induces antigen-specific T-cell responses, with the ability to induce apoptosis and necrosis [1].

MAGE-3 Antigen (167-176) (human) is an eight-amino-acid polypeptide epitope for HLA-B44 molecules, encoded by the melanoma antigen gene (MAGE) [1].

Tisagenlecleucel (CTL019), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, selectively targets and eradicates CD19-expressing B cells, and is utilized in the study of refractory aggressive diffuse large B-cell lymphoma [1] [2].

Hepatitis B Virus Pre-S Region (120-145) is a preS2 peptide that effectively blocks the attachment of single-chain Fv fragment (scFv) or IgG to recombinant Hepatitis B surface antigen (r-HBsAg) [1].